Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments
Ultherapy PRIME is the latest ultrasound technology with real-time imaging that provides a truly personalized and long-lasting* lift where it’s most beneficial for each patient.
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of Ultherapy PRIME – a noninvasive treatment that provides a truly personalized and long-lasting* lift of the skin in one session with zero downtime.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240923820281/en/
Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments (Photo: Business Wire)
The Ultherapy PRIME platform is the evolution of Ultherapy®, which has been recognized as the Gold Standard for nonsurgical lifting and skin tightening due to its large body of clinical evidence, well-established mechanism of action (MOA) and high patient satisfaction.1,2,3 Built on a legacy of proven, natural-looking outcomes, Ultherapy PRIME redefines the future of non-invasive skin lifting and tightening by uniquely combining advanced ultrasound technology, vivid real-time imaging and proven results. These advancements promote long-lasting* results paired with healthier-looking skin.1,2,3,4,5
The platform features a modern design with an advanced operating system, delivering 10x faster processing power, elevated ergonomics and seamless workflows for aesthetic health care professionals. Additionally, with a 35% larger screen and brighter, crisp images from all angles, Ultherapy PRIME offers a vivid visualization experience for a truly personalized, long-lasting* lift patients can see.**
“The launch of Ultherapy PRIME demonstrates our commitment to persist in innovation,” said Bob Rhatigan, CEO, Merz Aesthetics. “As the leader in noninvasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform and as a proven technology*** and customizable, long-lasting* treatment option.”
Ultherapy PRIME’s unique technology with real-time visualization goes beyond other noninvasive treatments to target the right collagen and elastin-rich layers of the tissue at multiple depths, delivering consistent and precise energy where the patient needs it the most.1,2,3,4,6,7 Ultherapy PRIME’s mechanism of action allows for personalized skin lifting outcomes through collagen and elastin stimulation, which can last up to a year or more.1,2,3,4,6,7 It is a great treatment option for all skin types and skin tones to maintain a youthful, healthy appearance in just one session with zero downtime.1
With three million Ultherapy treatments performed around the world, Ultherapy PRIME builds on an impressive legacy of lifts of the skin on the brows, area under the chin and neck and improves lines and wrinkles on the décolleté.1,2,3 With Ultherapy’s 95% patient satisfaction at year one and one of the strongest clinical bodies of evidence cited in over 120 publications and 56 clinical studies,2,4 Ultherapy PRIME is built on a legacy of safe and effective treatments. Ultherapy PRIME is The Lift You Can SEE.
“Now more than ever, patients seek treatments tailored to their unique skin needs. This is why Ultherapy is a cornerstone of my practice,” said world-renowned, board-certified dermatologist Sabrina Fabi, MD. “The new Ultherapy PRIME platform offers all the signature benefits of Ultherapy for noninvasive, long-lasting* lifting, now with significant advancements. Ultherapy PRIME improves the quality of the skin, catering to diverse patient needs with all skin types seeking a noninvasive lift and a younger, healthier appearance in just one session and no downtime.”
To learn more about Ultherapy PRIME, visit Ultherapy.com and follow @Ultherapy on Instagram.
*results can last up to a year or more 1,4
** in comparison to the previous version
***based on clinical studies conducted with Ultherapy legacy device
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
About Ultherapy®:
The noninvasive Ultherapy® procedure is intended for dermatological sculpting and lifting of the dermis on the upper face, lower face, neck and décolleté. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product information.
References:
- Ulthera® Instructions for Use
- Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
- Park JY, et al. Customized Treatment Using Microfocused Ultrasound with Visualization for Optimized Patient Outcomes: A Review of Skin tightening Energy Technologies and a Pan-Asian Adaptation of the Expert Panel’s Gold Standard Consensus. J Clin Aesthet Dermatol. 2021;14(5): E70-E79.
- Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
- Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
- Sasaki G, Grossman J, Fabi SG, et al. Stimulation of Collagen Synthesis in Human Skin Following Microfocused Ultrasound Therapy. Presented at the ASDS 2018 Annual Meeting.
- White WM, Makin IR, Barthe PG, Slayton MN, Gliklich RE. Selective creation of thermal injury zones in the superficial musculoaponeurotic system using intense ultrasound therapy: a new target for non-invasive facial rejuvenation. Arch Facial Plast Surg. 2007;9(1):22-29.
© 2024 Merz North America, Inc., Merz, and Merz Aesthetics are trademarks or registered trademarks of Merz Pharma GmbH & Co. KGaA in the EU and/or certain other countries. Ultherapy, Ulthera are trademarks and/or registered trademarks of Ulthera, Inc. in the EU and/or certain other countries. Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and International patents to which Ulthera, Inc. has rights are issued, published, or pending.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923820281/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 12:00:00 CEST | Press release
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filingsPhase 1 study of BCL2 inhibitor sonrotoclax plus BRUKINSA® elicited deep responses – 96% ORR in R/R CLL and 79% ORR in R/R MCL patients – with no new safety signals in the latest resultsBTK degrader BGB-16673 shows strong early results in hard-to-treat populations BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 10:17:00 CEST | Press release
Fortune ranking aligns with Infobip’s innovative efforts in the IT industry and digital infrastructure Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involv
Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off12.6.2025 09:00:00 CEST | Press release
The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact. During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development framework and positioning the organization as a venture builder in neurotechnology. Under his leadership, six breakthrough technologies were successfully spun out into operational startup companies: Clee Medical SA, Brainscape Medical SA, Dataflight Ltd, BrainQuant SA, Aleos Bio SA, and ABILITY Neurotech SA. In parallel, Craig led the onboarding of aligned startups such as Dandelion Science Corp. and dEEGtal Insights SA, strengthening our AI and neurotech ecosystem. He also contributed to Series A investments in two Wyss-affilia
SmartStream Brings AI-Powered Data Management to the Insurance Sector12.6.2025 09:00:00 CEST | Press release
SmartStream, the financial Transaction Lifecycle Management (TLM®) and solutions provider, has announced the expansion of its AI-driven reconciliation and data management platform, SmartStream Air, into the insurance sector. This move aims to help insurers tackle fragmented data challenges, reduce operational costs, and strengthen compliance through robust audit trails. As the insurance industry struggles with limited digital maturity, it faces mounting pressure from increasing transaction volumes, persistent data quality issues, and the complex demands of evolving regulations such as IFRS 17 and DORA. In this environment, the need for advanced, rapidly deployable SaaS data management solutions has never been more urgent. Addressing these challenges requires a fundamental transformation in how insurers manage systems, streamline operations, and ensure data integrity across the enterprise. SmartStream Air leverages cutting-edge AI to reconcile and manage high volumes of data, for exampl
Westlake Epoxy Announces Strategic Collaboration With Alpha Recyclage Composites to Advance Composites Recycling12.6.2025 08:00:00 CEST | Press release
Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy will collaborate with Alpha Recyclage Composites to support them in scaling up the recycling capacity for carbon fiber composite materials. This collaboration will provide support to Westlake’s composite customers in their development of improved circular options for both production (scrap or off spec composite materials that otherwise become waste) and end-of-life waste. The recovery of the carbon fibers from composite materials for reuse in new or emerging applications aims to establish a more sustainable alternative to traditional disposal methods such as landfilling and incineration. Alpha Recyclage Composites, a family-owned company based in Toulouse and Castelsarrasin, France, specializes in recycling carbon-fibers-reinforced composites through a patented steam pyrolysis process. This innovative technology preserves the performance qualities of the carbon fibers used in composite materials recovered from applica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom